Oct 2 (Reuters) - Bionomics Ltd (BNO) :
- UPDATES ON PHASE 2 POST TRAUMATIC STRESS DISORDER TRIAL RESULTS
- TRIAL DID NOT MEET PRIMARY ENDPOINT OF DECREASE IN PTSD SYMPTOMS AS MEASURED BY CAPS-5 AT 12 WEEKS
- BNC210 TREATMENT WAS SAFE AND WELL TOLERATED
Source text (http//reut.rs/2OqJRF6)
(([email protected];))
News: BNO Bionomics Ltd Updates On Phase 2 Post Traumatic Stress Disorder Trial Results
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
